がん研セミナー（9月25日）のお知らせ

演題：CD4⁺ T cells and the prevention of cancer relapse after personalized immunotherapy

演者：Professor Hans Schreiber (Department of Pathology, The University of Chicago)

抄録：Achieving curative treatment of solid tumors remains the challenge of cancer therapy despite advances using checkpoint inhibitors or adoptive transfer of tumor-infiltrating T cells. These treatments can be curative or achieve long-term survival, but only in a fraction of patients and certain types of cancers. Relapse is common. When treatments are effective, mutant neoantigens seem to be the relevant immunological targets. Most of these neoantigens are encoded by nsSNVs (nonsynonymous single nucleotide variants) also referred to as “individually specific” or “unique” antigens because they differ between each cancer of a given individual even when cancers are of the same histologic type and site of origin. While the field is heavily focused on CD8⁺ T cells evidence will be presented that adoptive transfer of mutation-specific CD8⁺ T cells is commonly followed by relapse and that mutation-specific CD4⁺ T cells are essential for preventing cancer relapse after therapy of solid tumors.

日時：２０１９年９月２５日（水） １２：００〜１３：００

場所：吉田記念講堂

連絡先：清谷一馬（内線５３６２）

＊外部の研究者のご来聴を歓迎いたします。尚、本セミナーの内容は専門的であり、医学・生物分野の研究に携わる方を対象としております。